| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BioStem Technologies, Inc. Common Stock
$3.09
-0.73 (-19.06%)
Market Cap
55.15 M
EPS
-
P/E Ratio
-
Value Trade
256.19 K
-18.68 %
Week
-16.03 %
1 Month
-24.5 %
3 Month
-24.5 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
332.42 K
52 Week Range
-
% held by Insiders
29 %
% held by Institutions
-
Enterprise Value
48.19 M
Total Shares
17.83 M
Short %
1.06 %
Float Shares
12.66 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioStem Technologies, Inc. Common Stock
16Total events
3Upcoming
1Tier-1 (high impact)
2026 – 2026Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BSEM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BSEM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-BSEM
Sep 30, 2026▼ -19.1%today
BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
BioStem Technologies has announced a private placement to raise $3 million by issuing shares and warrants. The offering, priced at $4.08 per share, includes Series A and B warrants, with potential additional proceeds of $5.6 million if fully exercised. The funds will be used for working capital and general corporate purposes, pending customary closing conditions.
Read more →-BSEM
Sep 18, 2026▲ +8.7%on this news
BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility
BioStem Technologies has announced a $40 million Committed Equity Facility with Roth Principal Investments. This facility allows BioStem to issue shares at its discretion, providing flexible access to capital for working and corporate purposes. The company plans to file a registration statement with the SEC for the resale of shares, although there are risks related to market conditions and shareholder dilution.
Read more →-BSEM
Sep 4, 2026BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
BioStem Technologies has announced that its products VENDAJE and VENDAJE AC are now available through contracts with Vizient and Premier, enhancing access for hospitals. This marks a significant step in expanding the reach of BioStem's wound care solutions. The CEO emphasized the importance of these agreements in supporting the company's commercial strategy and patient care.
Read more →-BSEM
Sep 3, 2026BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
BioStem Technologies Inc. (BSEM) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company's fireside chat will be accessible on September 11, 2026. BioStem focuses on developing and commercializing perinatal tissue allograft products, leveraging advanced processing technologies to enhance tissue preservation.
Read more →-BSEM
Aug 14, 2026▼ -6.5%on this news
BioStem Technologies to Present at the Sidoti MicroCap Conference
BioStem Technologies Inc. will present at the Sidoti MicroCap Virtual Conference on August 19, 2026. The presentation will be accessible live and in archive on the company's investor relations website. BioStem specializes in regenerative medicine, focusing on perinatal tissue allograft products and has a strong commitment to quality and innovation.
Read more →-BSEM
Aug 12, 2026▼ -18.4%on this newsshared move
BioStem Technologies Reports Second Quarter 2026 Financial Results
BioStem Technologies reported a 29% sequential revenue growth for Q2 2026, reaching $7.9 million. The company uplisted to the Nasdaq Capital Market and raised its full-year revenue guidance. Despite the positive revenue growth, BioStem recorded a net loss of $9.0 million, highlighting ongoing operational challenges.
Read more →-BSEM
Aug 6, 2026BioStem Technologies Announces Nasdaq Uplisting
BioStem Technologies Inc. has announced its uplisting to The Nasdaq Capital Market, with trading set to begin on August 7, 2026. This move is viewed as a milestone for the company, aimed at improving capital access and market visibility. CEO Jason Matuszewski highlighted the uplisting's potential to attract talent and support growth. Shareholders will not need to take any action regarding the listing.
Read more →Competitive Position
How BSEM ranks across every disease it competes inCompetitive Position is a premium feature
See how BSEM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial